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Abstract
 
Exposure of bone marrow–derived macrophages (BMDMs) to low concentrations of 
 
Bacillus
anthracis
 
 lethal toxin (LT), whose catalytic subunit is lethal factor (LF), results in induction of a
robust apoptotic response dependent on activation of Toll-like receptor (TLR)4. A similar
TLR4-dependent apoptotic response is observed when BMDMs are infected with live 
 
B. anthracis
 
(Sterne strain). However, TLR4 is considered to be a specific signaling receptor for lipopolysaccha-
ride (LPS), a typical product of gram-negative bacteria, whereas 
 
B. anthracis
 
 is gram-positive.
To understand how 
 
B. anthracis
 
 can activate TLR4, we analyzed its culture supernatants and
found them to contain a potent TLR4-stimulating activity that can also induce apoptosis in
macrophages in which the antiapoptotic p38 MAP kinase (whose activation is prevented by
LF) was inhibited. Purification of this activity suggested it consists of anthrolysin O (ALO), a
member of the cholesterol-dependent cytolysin (CDC) family. We show that recombinant
ALO can activate TLR4 in a manner independent of LPS contamination and, together with
LT, can induce macrophage apoptosis. We also provide genetic evidence that ALO is required
for induction of macrophage apoptosis in response to infection with live 
 
B. anthracis
 
 and that
other CDC family members share the ability to activate TLR4.
Key words: macrophage • anthrax • innate immunity • apoptosis • infection
 
Introduction
 
Bacillus anthracis
 
 is a highly virulent gram-positive bacillus
that is the causative agent of different forms of anthrax (1).
At least part of the extreme virulence of 
 
B. anthracis
 
 is due
to production of several exotoxins or virulence factors: lethal
factor (LF), edema factor (EF), and protective antigen (PA;
references 2, 3). Although PA binds to receptors expressed
on the surface of host cells and allows cellular entry of LF
and EF (4, 5), LF and EF possess essential enzymatic activities
that alter host cell signaling (6–8). LF is metalloproteinase
with unique specificity to mitogen-activated protein kinase
(MAPK) kinases (MKKs), which severs the COOH-terminal
MKK catalytic domain from the NH
 
2
 
-terminal regulatory
domain (8, 9). This cleavage results in dismantling of MAPK
activation cascades (8), whose normal function depends on
interaction of the NH
 
2
 
-terminal MKK regulatory domain
with upstream MKK kinases (MEKKs or MAP3Ks) and
downstream MAPKs (10). We found that incubation with
low amounts of 
 
B. anthracis
 
 lethal toxin (LT), a hetero-
oligomer of PA and LF (2, 3), renders macrophages sensi-
tive to LPS-induced apoptosis by preventing activation of
the p38 MAPK pathway (11). This response, which depends
on the proteolytic cleavage of MKK6 by LF, can be mim-
icked by the use of low molecular weight p38 inhibitors,
such as SB202190 (11). More recently, we demonstrated
that infection of BM-derived macrophages (BMDMs) with
live 
 
B. anthracis
 
 (Sterne strain) also results in extensive apop-
tosis that depends on signaling from the LPS-responsive Toll-
like  receptor (TLR)4, which activates the proapoptotic
double-stranded, RNA-dependent protein kinase PKR (12).
However, 
 
B. anthracis
 
 is a gram-positive bacterium that
does not produce LPS and, thus, it remained to be identi-
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fied which component of 
 
B. anthracis
 
 activates TLR4 and
induces apoptosis of macrophages exposed to LF. In this
work, we sought to identify a specific TLR4 agonist from
 
B. anthracis
 
. This investigation revealed that anthrolysin O
(ALO), a cholesterol-dependent cytolysin (CDC) secreted
by 
 
B. anthracis
 
 (13), specifically targets TLR4 and acts to-
gether with LT to induce macrophage apoptosis. Other
members of the CDC family were also found capable of
TLR4 activation.
 
Materials and Methods
 
Mice and Macrophages. 
 
C57BL/6J, C3H/OuJ, C3H/HeJ,
B6.MRL-
 
Tnfrsf6
 
lpr
 
/J (Fas
 
lpr/lpr
 
), and C57BL/6-
 
Tnfrsf1a
 
tm1Imx
 
(TNFR1
 
   
 
) mice were obtained from The Jackson Laboratory.
IFNR1
 
   
 
 mice in the 129/SvEv background were obtained
from E. Raz (University of California, San Diego, CA). BMDMs
were prepared as described previously (11).
 
Reagents. B. anthracis
 
 cell walls were purchased from List Bio-
logical Laboratories, Inc. Other reagents used for treatment of
BMDMs included the following: LPS (
 
Escherichia
 
 
 
coli
 
; Sigma-Ald-
rich), peptidoglycan (Fluka), poly(I-C) (Amersham Biosciences),
CpG oligodeoxynucleotide (TIB MOLBIOL), Pam
 
3
 
CSK
 
4
 
 (EMC
Microcollections), and R-848 (GLS Synthesis). SB202190 was
from Calbiochem.
 
Bacterial Strains, Culture, and Infection.  B.  anthracis
 
 Sterne
strain 7702 and its derivatives were described previously (13).
Bacteria were grown in brain heart infusion broth (BHI; Difco),
without added bicarbonate, with shaking (200 revolutions/min)
at 37
 
 
 
C in an air shaker incubator or on BHI agar in a humidified
incubator. Bacterial infection of macrophage cultures was de-
scribed previously (12).
 
Purification of ALO from Bacterial Culture Supernatants. 
 
All
buffers used in dialysis and column chromatography were pre-
pared with double-distilled and autoclaved water and contained
protease inhibitors (10 
 
 
 
M phenylmethylsulfonyl fluoride, 20
nM pepstatin A, 6 nM leupeptin, and 20 
 
 
 
M bisbenzamidine).
The buffers were confirmed to be endotoxin free by testing their
ability to induce TNF-
 
 
 
 expression in macrophages. To purify
macrophage-stimulating activity from 
 
B. anthracis
 
 culture super-
natants, bacteria were grown in BHI broth until OD595 reached
1.0. After removing bacteria by centrifugation, the supernatant
(two liters) was filtered through 0.2-
 
 
 
m-pore Nylon filters (Nal-
gene), concentrated up to 80-fold on a Centricon Plus-20 Filter
Device (Millipore), and dialyzed in buffer D100 (20 mM Tris-Cl,
pH 7.0, 100 mM NaCl, and 0.1 mM EDTA). 84 mg of protein
in the culture concentrate were applied to a DEAE-sepharose
column (10 ml) equilibrated with buffer D100. The macrophage-
stimulating activity (see Results) was found to pass through this
column under this particular loading condition. Proteins in the
flow-through fraction (61 mg) were equilibrated in buffer S50
(20 mM Hepes-KOH, pH 7.0, 50 mM NaCl, and 0.1 mM
EDTA) by dialysis and applied to a Mono S column (1 ml per 20
mg of protein) equilibrated with buffer S50. After washing with
buffer S50, bound proteins were eluted with a linear gradient of
50–1,000 mM NaCl. The major peak fractions of macrophage-
stimulating activity (3.1 mg) were pooled and mixed with an
equal volume of 100 mM Tris-Cl, pH 7.0, and 3 M (NH
 
4
 
)
 
2
 
SO
 
4
 
,
and applied to a 0.5-ml phenyl-sepharose column equili-
brated with buffer P1500 (50 mM Na
 
2
 
HPO
 
4
 
, pH 7.0, 1.5 M
(NH
 
4
 
)
 
2
 
SO
 
4
 
, and 0.1 mM EDTA). After washing with buffer
P1500, bound proteins were eluted with an inverse linear gradi-
ent of 1.5 to 0 M (NH
 
4
 
)
 
2
 
SO
 
4
 
. The phenyl-sepharose fractions ac-
tive in macrophage stimulation were stored at 
 
 
 
80
 
 
 
C.
 
Preparation of Recombinant Proteins. 
 
Recombinant LF, PA,
and CDCs were expressed in and purified from 
 
E. coli
 
 strain
BL21 (DE3) bearing the appropriate plasmid construct as de-
scribed previously (13–15). Purified listeriolysin O (LLO) and
LLO expression vector were provided by D. Portnoy (University
of California, Berkeley, CA), and perfringolysin O (PFO) and
streptolysin O (SLO) expression vectors by R. Tweten (Univer-
sity of Oklahoma Health Sciences Center, Oklahoma City, OK).
The analyses of macrophages’ activation by CDCs (see Figs. 3, B
and C, and 6 A) were performed with proteins synthesized in
reticulocyte lysates using T7 expression plasmids harboring a
CDC gene and the TNT T7 kit (Promega).
 
Protein Analysis.
 
Whole-cell extracts for immunoblot analysis
were prepared with lysis buffer (20 mM Hepes-KOH at 150 mM
NaCl, pH 7.6, 10% glycerol, 1% Triton X-100, 25 mM 
 
 
 
-glyc-
erophosphate, 2 mM EDTA, and protease inhibitors) and sub-
jected to SDS-PAGE. Proteins transferred to nitrocellulose mem-
brane were probed with rabbit antiserum against recombinant
ALO (13), and antibodies directed against actin (Sigma-Aldrich),
iNOS, phospho-p38
 
 
 
, p38
 
 
 
, and I
 
 
 
B
 
 
 
 (all from Santa Cruz
Biotechnology, Inc.), and the immune complexes were visualized
with the ECL Western blot reagent (Pierce Chemical Co.).
TNF-
 
 
 
 secretion was measured by an ELISA (R&D Systems).
 
RNA Analysis. 
 
Total RNA was isolated using the RNAwiz
reagent (Ambion). For real-time PCR analysis, cDNAs were syn-
thesized with the Superscript II reverse transcriptase system (In-
vitrogen). An amount of cDNA equivalent to 0.2 
 
 
 
g of total
RNA was subjected to 40 cycles of amplification consisting of a
15-s incubation at 95
 
 
 
C and a 1-min incubation at 60
 
 
 
C. Output
was monitored using SYBR green core reagents and the ABI
Prism 7700 System (PE Applied Biosystems). The results were
normalized to the level of cyclophilin mRNA. Individual primer
sequences are available upon request.
 
Measurement of Cell Viability and Hemolysis. 
 
TUNEL assay
and Hoechst staining were performed as described previously
(11). MTT assay and annexin V staining were performed using an
MTT kit and annexin V-Alexa 568, respectively, according to
the manufacturer’s instructions (Roche). The hemolysis assay was
performed by incubating mouse erythrocytes (whole blood di-
luted 10-fold with phosphate-buffered saline) with CDCs for 30
min at 37
 
 
 
C, centrifuging the mixture at 8,000 
 
g
 
 for 1 min, and
measuring A350 of the supernatant. The relative optical density
was compared with that of erythrocytes treated with 0.1% Triton
X-100 and used to determine percentage of hemolysis.
 
Immunodepletion of ALO. 
 
0.4 ml of culture supernatants was
mixed with 5 
 
 
 
l of ALO-specific antiserum on a rotating wheel
for 12 h at 4
 
 
 
C. 50 
 
 
 
l of protein A–agarose beads was added and
incubated for 1 h. Samples were briefly centrifuged to precipitate
the beads, and supernatants were collected for further analyses.
 
Results
 
Identification of Macrophage-stimulating Activity from B. an-
thracis Culture Supernatant. 
 
To identify the TLR4 agonist
from 
 
B. anthracis
 
 that is required for triggering the apoptosis
of LT-treated macrophages, we tested 
 
B. anthracis
 
 cell wall
preparations and culture supernatants for their ability to
stimulate TNF-
 
 
 
 gene expression and induce apoptosis of
BMDMs in the presence of the p38 inhibitor SB202190.
Treatment of BMDMs with a crude, commercially avail- 
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able 
 
B. anthracis
 
 cell wall preparation did not strongly in-
duce TNF-
 
 
 
 mRNA expression or apoptosis (Fig. 1 A, I
and II). However, a 
 
B. anthracis
 
 culture supernatant in-
duced both TNF-
 
 
 
 mRNA and apoptosis under the same
conditions (Fig. 1 A, III). The TNF-
 
 
 
– and apoptosis-
inducing activity in the culture supernatant was sensitive to
proteinase K digestion (Fig. 1 A, IV), suggesting that a pro-
teinaceous component is responsible for both activities. As
only TLR4 agonists, but not agonists for other TLRs, can
strongly potentiate macrophage apoptosis in the presence
of SB202190 (Fig. 2 A and references 11, 12), this protein
is likely to act as a TLR4 agonist.
To identify the protein responsible for this activity, the
 
B. anthracis
 
 culture supernatant was sequentially purified
through DEAE-sepharose, Mono S, and phenyl-sepharose
chromatography columns. On the phenyl-sepharose col-
umn, the TNF-
 
 
 
– and apoptosis-inducing activities cofrac-
tionated as a single peak centered at fraction 26 (Fig. 1 B).
Analysis of the composition of the different column frac-
tions revealed that a 63-kD polypeptide copurified with
both activities (Fig. 1 B). Among the secreted proteins pre-
dicted by the 
 
B. anthracis
 
 genome sequence (16), we noted
the presence of ALO, a CDC, encoded by the BA3355
gene (13). The ALO polypeptide consists of 512 amino ac-
ids with the NH
 
2
 
-terminal 35 residues coding for a signal
peptide, a size consistent with the aforementioned 63-kD
band. Of note, it was recently shown that pneumolysin, a
closely related CDC of 
 
Streptococcus pneumoniae
 
, is capable of
activating TLR4 (17). This raised the possibility that the
TNF-
 
 
 
 and apoptosis-inducing activity of the 
 
B. anthracis
 
culture supernatant may be attributable to ALO. Hence, we
analyzed the phenyl-sepharose fractions by immunoblotting
with anti-ALO antibody and found that ALO indeed copu-
rified with the 63-kD protein, as well as the macrophage-
stimulating and apoptosis-inducing activities (Fig. 1 B).
 
Activation of Macrophages by ALO via TLR4. 
 
To di-
rectly test whether ALO can stimulate macrophages in a
TLR4-dependent manner, we prepared pure recombinant
ALO (rALO) by expression in 
 
E. coli
 
. Treatment of BM-
DMs with rALO or other TLR agonists with different re-
ceptor specificities resulted in a strong induction of TNF-
 
 
 
mRNA (Fig. 2 A). To compare the gene induction speci-
ficity of ALO to those of other TLR agonists, we exam-
ined the mRNA levels of other cytokines including IL-1
 
 
 
,
IL-1
 
 
 
, and IL-6. Although TNF-
 
 
 
 was induced to similar
extents by ALO and the different TLR agonists, the IL-1
and IL-6 genes were most strongly induced by ALO and
LPS, but were less responsive to other TLR agonists (Fig. 2
A). Furthermore, treatment of BMDMs with either ALO
or the different TLR agonists in conjunction with SB202190
revealed that only ALO and LPS were able to cause a ro-
bust apoptotic response (Fig. 2 A).
To specifically examine the role of TLR4 in the response
to ALO, we prepared BMDMs from wild-type (C3H/OuJ)
and TLR4 mutant (C3H/HeJ) mice and compared their re-
sponses with ALO treatment. ALO induced activation of
p38 MAPK and degradation of I
 
 
 
B
 
 
 
 in TLR4 wild type,
but not in TLR4 mutant, BMDMs (Fig. 2 B). The TLR4
mutant BMDMs showed no defect in their response to
the TLR2 agonist-synthetic bacterial lipopeptide (sBLP;
Pam
 
3
 
CSK
 
4
 
; Fig. 2 B). ALO also failed to induce TNF-
 
 
 
and IL-6 gene expression in TLR4 mutant BMDMs (see
Fig. 6 C and not depicted). These observations indicate that
ALO activates macrophages via TLR4. To rule out the pos-
sibility that TLR4 activation by recombinant ALO is due to
the presence of contaminating LPS in the preparation, we
treated BMDMs with ALO, LPS, and taxol, another TLR4
Figure 1. Identification of a macrophage-stimulating activity in B. anthracis
culture supernatant. (A) C57BL/6J BMDMs were left untreated (I),
treated with a B. anthracis cell wall preparation (II), or with B. anthracis
culture supernatant before (III) and after (IV) proteinase K pretreatment.
After 4 h, total RNA was isolated, and relative expression of TNF- 
mRNA (black bars) was determined by real-time PCR. In a separate ex-
periment, BMDMs were preincubated with 10  M SB202190 for 2 h,
and treated as described before. After 24 h, cell viability (white bars) was
measured by the MTT assay. (B) Partially purified B. anthracis culture super-
natant was fractionated on a phenyl-sepharose column. Column fractions
were tested for their ability to induce TNF-  expression (top) or macrophage
apoptosis (middle) as described before. The protein composition and
ALO-content of the column fractions were examined by SDS-PAGE and
silver staining and immunoblotting with an anti-ALO antibody (bottom). 
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agonist, in the presence of polymyxin B, which blocks LPS
binding to TLR4. Activation of p38 MAPK by LPS, but
not by ALO or taxol, was inhibited by polymyxin B (Fig. 2
C). Polymyxin B neutralized the activity of LPS at concen-
trations as high as 0.5 
 
 
 
g/ml (unpublished data). We also
examined the requirement of serum for biological activity
and the proteinase K sensitivity of ALO and LPS. TLR4 ac-
tivation by LPS depends strictly on factors such as soluble
CD14 and LPS-binding protein that are provided by inclu-
sion of serum (18). We found that p38 MAPK activation in
macrophages by rALO can occur in serum-free medium, in
which LPS fails to activate p38 MAPK (Fig. 2 D). The con-
verse was observed after proteinase K digestion. Although
proteinase K treatment completely abolished the ability of
ALO to activate p38 MAPK, the activity of LPS was largely
unaffected (Fig. 2 D). Together, these experiments un-
equivocally demonstrate that TLR4 activation by ALO is
not due to contamination with LPS, whose activity is pro-
teinase K resistant and serum dependent.
 
TLR4 Activation by ALO Independent of the Cytolytic Ac-
tivity.
 
It has been shown that certain proteins derived
from damaged host cells can also activate TLR4 (19). This
raised the possibility that ALO may activate TLR4 indi-
rectly by lysis of macrophages leading to the release of en-
dogenous TLR4 agonists.
To address this possibility, we first examined whether
ALO by itself exerts a cytotoxic effect on BMDMs at a
range of concentrations that support TNF-
 
 
 
 induction.
Although ALO manifested strong hemolytic activity on
red blood cells at concentrations lower than those required
for TNF-  mRNA induction, no significant cytotoxicity
toward BMDMs was observed, even at the highest ALO
concentration tested (Fig. 3 A). Hence, macrophage acti-
vation by ALO is not accompanied by host cell permeabili-
zation. To obtain more direct evidence that TLR4 activa-
tion by ALO does not involve host cell permeabilization,
we generated a derivative (designated  D4) of ALO
that lacks a carboxy (COOH)-terminal fragment spanning
amino acids 409–512. This COOH-terminal fragment is
homologous to domain 4 of PFO that possesses a choles-
terol-binding activity and plays an indispensable role in
forming pores in cholesterol-containing membranes (20).
Full-length (FL) ALO and  D4 were produced by in vitro
translation in reticulocyte lysates and tested for hemolytic
activity. FL ALO, but not  D4, exhibited hemolytic activ-
ity against mouse erythrocytes (Fig. 3 B), demonstrating
the importance of the PFO domain 4–like region of ALO
for pore formation. However, both of the in vitro trans-
lated proteins were capable of inducing TNF-  gene ex-
pression by BMDMs, whereas a control lysate programmed
with an empty backbone plasmid was inactive (Fig. 3 C).
This finding indicates that ALO activates macrophages in-
dependently of its cytolytic activity. In an alternative ap-
proach, we examined culture supernatant of ALO-treated
Figure 2. Macrophage activation by ALO
is TLR4 dependent. (A) BMDMs were left
untreated ( ), or treated with 50 ng/ml re-
combinant ALO, or other TLR agonists,
including 10  g/ml peptidoglycan (PGN), 1
 g/ml synthetic bacterial lipopeptide (sBLP;
Pam3CSK), 10  g/ml poly(I-C), 100 ng/ml
LPS, 1  M R-848, or 1  M CpG oligode-
oxynucleotide (CpG ODN). Total RNA
was analyzed as in Fig. 1 A for expression
of different cytokine mRNAs (black bars).
BMDMs were also preincubated with 10  M
SB202190 for 2 h and treated as before. Cell
viability was measured by the MTT assay
(white bars). (B) BMDMs from C3H/OuJ
(tlr4OuJ/OuJ; Ou) or C3H/HeJ (tlr4HeJ/HeJ; He)
mice were incubated with 50 ng/ml ALO,
100 ng/ml LPS, or 1  g/ml sBLP. At the
indicated time points, cell lysates were pre-
pared and analyzed by immunoblotting with
the antibodies indicated on the left for I B 
degradation and p38 activation (appearance
of phosphorylated p38 ). (C) BMDMs
(C57BL/6J)  were preincubated with or
without 25  g/ml polymyxin B for 1 h and
treated with 50 ng/ml ALO, 10  M taxol,
or 100 ng/ml LPS. After 15 min, cell lysates
were prepared and analyzed as in B. An
I B  signal indicates no IKK activation,
whereas a phospho-p38  signal indicates p38
activation. (D) BMDMs (C57BL/6J) were
incubated with LPS or ALO in either serum-
containing or serum-free media (SFM) before
or after pretreatment with proteinase K (PK).
After 15 min, cell lysates were prepared and
analyzed as in B for p38 activation.Park et al. 1651
as well as lysed macrophages for TLR4-stimulating activi-
ties. To permeabilize the membranes of BMDMs, the cells
were treated with melittin, a bee venom toxin with potent
cytolytic activity (21), or subjected to two cycles of freez-
ing and thawing. Treatment with melittin or freezing–
thawing induced significant levels of cell permeabilization
as monitored by staining with the membrane-impermeable
dye Hoechst 33258 (Fig. 3 D). However, as in Fig. 3 A,
little or no comparable cytolysis was observed upon ALO
treatment.
The conditioned media (CM) from these cultures were
applied to fresh BMDMs, and TNF-  mRNA induction
was analyzed. Although the CM of ALO-treated cells po-
tently induced TNF-  mRNA, those of cells damaged by
melittin treatment or freeze–thawing did not (Fig. 3 D).
The macrophage-stimulating activity contained in the CM
of ALO-treated cells may still originate from endogenous
host factors that are specifically released from BMDMs in
response to ALO treatment. To investigate this possibility,
the CM from ALO-treated cells was depleted of ALO with
an ALO-specific antiserum and applied to untreated BM-
DMs. The ALO-depleted CM lost its ability to activate
TNF-  mRNA induction, but CM immunodepleted with
preimmune serum was still capable of inducing TNF- 
mRNA (Fig. 3 E). Therefore, macrophage activation by
CM from ALO-treated cells is not due to any protein other
than ALO itself. Together, these independent lines of evi-
dence unequivocally demonstrate that TLR4 activation by
ALO is not a secondary response to host cell damage
caused by the cytolytic activity of ALO.
Macrophage Apoptosis Induced by Treatment with B. anthracis
Proteins. As we identified ALO as a TLR4 agonist that
can lead to macrophage apoptosis under conditions of
SB202190 pretreatment, we checked if it can also act to-
gether with B. anthracis LF to induce macrophage apopto-
sis. To this end, we used ALO, LF, and PA. The three B.
anthracis proteins were produced in E. coli and purified to
apparent homogeneity (Fig. 4 A). Addition of ALO, LF,
and PA to BMDMs induced apoptosis of the latter as
shown by either TUNEL assay or annexin V staining (Fig.
4 B). Each of the three proteins was indispensable for in-
duction of macrophage apoptosis. In a separate experiment,
different amounts of ALO were combined with fixed
amounts of LF and PA and the mixture was added to BM-
DMs. Under these conditions, ALO induced macrophage
apoptosis in a dose-dependent manner, but even at the
highest concentration tested did not induce apoptosis on its
own. This shows that the ability to induce macrophage ap-
optosis does not represent a nonspecific cytotoxic activity
of ALO.
As ALO induces expression of proinflammatory genes by
macrophages, the observed apoptotic response may repre-
sent a secondary response induced by one of these proin-
flammatory cytokines, such as TNF- . To address this issue,
we tested BMDMs harboring mutations in genes encoding
different proapoptotic cytokine receptors for their response
Figure 3. ALO activates TLR4 indepen-
dently of its cytolytic activity. (A) The levels of
hemolysis, macrophage cytolysis (permeability
to Hoechst 33258), and TNF-  mRNA induc-
tion were determined after treatment of either
erythrocytes or macrophages with the indicated
ALO concentrations. (B) Reticulocyte lysates
programmed with either an empty backbone
vector ( , pRSET-A), T7 expression vectors
for full-length (FL) ALO, or the  D4 deriva-
tive, lacking amino acids 409–512, were ana-
lyzed by immunoblotting with an ALO-specific
antibody. The hemolytic activity of the reticu-
locyte lysates was measured and is shown above
the immunoblot. (C) BMDMs (C57BL/6J)
were incubated with reticulocyte lysates pre-
pared as in B. After 4 h, total RNA was iso-
lated, and relative expression of TNF-  mRNA
(black bars) was determined by real-time PCR.
(D) BMDMs (C57BL/6J) were treated with
100 ng/ml ALO or 100  g/ml melittin, or sub-
jected to two cycles of freezing at  80 C and
thawing at 37 C. After 4 h, the level of cell per-
meabilization was analyzed by staining with
H33258 (left). The conditioned media (CM)
collected after the first treatment were applied
to fresh BMDMs and TNF-  mRNA induc-
tion was analyzed after 4 h by real-time PCR
(right). (E) CM collected from ALO-treated
cells was depleted with anti-ALO or preim-
mune serum (Mock). The level of ALO in the
immunodepleted CM was analyzed by immu-
noblotting and the TNF- –inducing activity of
the immunodepleted CM was analyzed as in D.TLR4 Activation by Cholesterol-dependent Cytolysins 1652
to ALO and SB202190. BMDMs from mice homozygous
for deletions or inactivating mutations in the genes for TNF
receptor 1, Fas, and the IFNR1 underwent apoptosis after
treatment with ALO and SB202190, similar to wild-type
BMDMs (Fig. 4 D). Only TLR4 mutant BMDMs were re-
sistant to the apoptotic effect of ALO and SB202190.
Requirement for ALO in B. anthracis-induced Macrophage
Apoptosis.  The aforementioned studies defined a minimal
set of B. anthracis proteins, including ALO, that can trigger
macrophage apoptosis in culture. Next, we examined the
contribution of ALO to macrophage apoptosis caused by
infection with live B. anthracis (12). BMDMs infected with
the wild-type Sterne strain of B. anthracis underwent apop-
tosis detected by staining with Hoechst 33258 (Fig. 5 A) or
by a TUNEL assay (Fig. 5 B). In contrast, macrophages in-
fected with the same multiplicity of infection of an ALO-
deficient mutant derived from the Sterne strain (13) exhib-
ited a considerably reduced apoptotic response (Fig. 5, A
and B). The inability of the  alo mutant to induce mac-
rophage apoptosis was rescued by transformation with a
plasmid containing the alo gene (Fig. 5, A and B, and refer-
ence 13). These results indicate that ALO is necessary for
the ability of B. anthracis to induce macrophage apoptosis,
which was previously shown to be TLR4 dependent (12).
TLR4-dependent Macrophage Activation by CDC from Dif-
ferent Gram-positive Bacteria.  ALO and pneumolysin are
closely related to other CDCs produced by gram-positive
pathogens. Our finding that ALO and pneumolysin (17)
activate TLR4 prompted us to test whether this property is
shared among other CDCs. Interestingly, it has been ob-
served that CDCs, such as LLO from Listeria monocytogenes
and SLO from Streptococcus pyogenes, can activate macro-
phages and mast cells to produce proinflammatory cyto-
kines and chemokines (22, 23). We explored the possibility
that CDCs may serve as gram-positive pathogen-associated
molecular patterns specific for TLR4. LLO and SLO, as well
as PFO from Clostridium perfringens and ALO, were pro-
duced by in vitro translation in reticulocyte lysates and ap-
plied to BMDMs. All of the in vitro–translated CDCs were
found to induce iNOS expression by BMDMs, whereas a
control lysate programmed with an empty backbone plas-
mid was inactive (Fig. 6 A). Hence, all four CDCs are ca-
pable of activating macrophages. Next, we tested recombi-
nant CDCs produced in and purified from E. coli for their
dependence on TLR4 for macrophage activation. First, we
measured TNF-  produced from BMDMs after treatment
with recombinant CDCs. All four CDCs induced TNF- 
secretion into the medium to similar extents (Fig. 6 B).
Figure 4. Reconstitution of macrophage
apoptosis with recombinant LF, PA, and ALO
proteins. (A) Recombinant LF, PA, and ALO
proteins were analyzed by SDS-PAGE and
Coomassie blue staining. (B) BMDMs
(C57BL/6J) were treated with different
combinations of 500 ng/ml recombinant
LF, 1  g/ml PA, and 50 ng/ml ALO as in-
dicated. After 24 h, the cells were analyzed
by TUNEL, DAPI, and annexin V staining.
(C) BMDMs were treated with 1  g/ml PA
and the indicated amounts of ALO in the
absence (white bars) or presence (black bars)
of 500 ng/ml LF. The number of apoptotic
cells was determined by annexin V staining.
(D) BMDMs from wild type (C57BL/6J),
TLR4 mutant (Tlr4HeJ/HeJ), IFNR1 knock-
out (Ifnar1   ), TNFR1 knockout (Tnfr1   ),
and Fas mutant (Faslpr/lpr) mice were prein-
cubated with 10  M SB202190 and treated
with 50 ng/ml ALO. At different time
points, cell viability was determined by
Hoechst 33258 staining. Cells that were not
stained were counted as viable cells.Park et al. 1653
TNF-  production induced by all of the CDCs was refrac-
tory to polymyxin B treatment (Fig. 6 B), showing that
LPS contamination is not responsible for macrophage acti-
vation by recombinant CDCs. Treatment of BMDMs with
increasing amounts of ALO, PFO, LLO, and SLO also re-
sulted in induction of TNF-  and IL-6 mRNAs (Fig. 6 C).
In most cases, the gene induction response reached its max-
imum at 100 ng/ml of CDCs (or  1.7 nM for an  60-kD
protein). In contrast, TLR4 mutant BMDMs did not re-
spond with cytokine gene expression to the same concen-
tration of any of the CDCs (Fig. 6 B). These results
strongly suggest that the ability to activate TLR4 is a gen-
eral property shared by CDCs from gram-positive bacteria.
Discussion
TLRs play pivotal roles in recognizing and resisting mi-
crobial infection (24, 25). Among the immediate outcomes
of the TLR-dependent immune response is the production
of cytokines by dedicated inflammatory cells such as mac-
rophages. The production and release of cytokines and
chemokines is responsible for the inflammatory response that
accompanies bacterial infection and, in the case of TLR4 ac-
tivation by LPS, can lead to septic shock (26). Several lines
of circumstantial evidence have suggested that B. anthracis
interacts with host immune cells through TLRs: B. anthracis
infection elicits a cytokine response in both mice and cul-
tured macrophages (27, 28) and causes macrophage apopto-
sis in a manner dependent on TLR4 signaling (12). None-
theless, the identity of the B. anthracis component that is
responsible for inducing cytokine and apoptotic responses in
macrophages was not hitherto known. It was reported pre-
viously that macrophages treated with very low doses of LT
produce TNF-  and IL-1  (29), suggesting a role for LT in
cytokine response. However, unlike TLR agonists, LT in-
duces IL-1  production by causing the release of mature IL-
1  derived from a presynthesized pool of IL-1  precursor
rather than activating IL-1  gene expression (30, 31). This
effect is reminiscent of the Shigella IpaB and Salmonella SipB
invasins, which cause IL-1  release through activation of
caspase-1 (32, 33). It is noteworthy that the pathological fea-
tures associated with LT-induced lethality in mice are also
quite different from those seen in B. anthracis–infected mice.
LT-injected mice manifest hypoxia-associated liver failure
and pleural edema without mounting the massive cytokine
response that usually accompanies either gram-negative or
gram-positive septic shock (34). Hence, LT alone does not
account for the inflammatory cytokine response that accom-
panies B. anthracis infections.
In this paper, we have identified the B. anthracis cytolysin
ALO as a potent TLR4 agonist that is responsible for in-
ducing cytokine gene expression and apoptotic responses in
macrophages. TLR4-specific activation of immune cells
appears to be a general property shared among gram-posi-
tive CDCs, including ALO, LLO, SLO, PFO, and pneu-
molysin (this paper and reference 17). It is well established
Figure 5. Requirement for ALO in B. anthracis–induced macrophage
apoptosis. (A) BMDMs (C57BL/6J) were infected with wild-type B. an-
thracis (7702), alo mutant (7702 alo), or alo mutant complemented with
the alo gene (7702 alo; pUTE544[Alo]) at a multiplicity of infection of
0.1. After 6 h, cell death was measured by H33258 staining. (B) BMDMs
were infected with B. anthracis as in A. After 12 h, cells were stained with
DAPI (blue) or TUNEL (green).
Figure 6. TLR4 activation by ALO and other CDCs of gram-positive
bacteria. (A) BMDMs (C57BL/6J) were incubated with reticulocyte lysates
programmed with either an empty backbone vector (Mock; pRSET-A), or
T7 expression vectors for ALO, perfringolysin O (PFO), listeriolysin O
(LLO), or streptolysin O (SLO). After 12 h, cell lysates were prepared and
analyzed by immunoblotting for iNOS induction. (B) BMDMs (C57BL/6J)
were preincubated with or without 25  g/ml polymyxin B for 1 h and
treated with100 ng/ml LPS or 50 ng/ml CDC proteins. After 12 h, culture
supernatants were collected and examined for TNF-  secretion by ELISA.
(C) BMDMs from C3H/OuJ (tlr4 OuJ/OuJ) or C3H/HeJ (tlr4 HeHeJ/HeJ) mice
were stimulated with the indicated amounts of recombinant ALO, PFO,
LLO, and SLO, or sBLP (1  g/ml). After 4 h, total RNA was isolated,
and the levels of TNF-  and IL-6 mRNA were measured by real-time PCR.TLR4 Activation by Cholesterol-dependent Cytolysins 1654
that CDCs are major virulence factors in gram-positive in-
fections (35–37). The mechanisms by which CDCs con-
tribute to pathogenesis in gram-positive infections have
been attributed thus far to their cytolytic activity and their
role in regulating intracellular compartmentalization of
pathogenic bacteria (38). In addition, SLO has been shown
to mediate vectorial transport of streptococcal proteins into
the cytoplasm of host cells (39, 40). Our results suggest that
the ability of CDCs to induce inflammatory and apoptotic
responses in host immune cells via TLR4 should be taken
into account in understanding their virulence mechanism
and can be a major contributor to gram-positive–induced
septic shock. Notably, cultured macrophages exhibit maxi-
mal cytokine gene induction at considerably lower molar
concentrations of CDCs ( 0.8 nM) than LPS ( 10 nM;
based on an average molecular mass of 10 kD).
We have defined a minimal set of three anthrax proteins
(ALO, LF, and PA) that can trigger macrophage apoptosis.
Identifying the critical interplay between ALO and LT in
modulating innate immune responses and inducing mac-
rophage apoptosis provides new insights to the development
of effective strategies for fighting inhalation anthrax, which
may improve the current therapeutic scheme based on the
use of antibiotics (41). Notably, LLO is a major target anti-
gen of antilisterial immunity (42, 43) and protective immu-
nity to L. monocytogenes can be induced by either an adoptive
transfer of LLO-reactive cytotoxic T lymphocytes (44) or
immunization with LLO-derived antigens (45, 46). There-
fore, the use of an ALO-directed vaccination in the prophy-
laxis of inhalation anthrax should be considered. Overall, we
suggest that ALO represents an important target for both the
development of vaccines and the design of antitoxin thera-
pies effective for preventing and treating anthrax diseases.
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